Five Prime Therapeutics Inc.
www.fiveprime.com
Latest From Five Prime Therapeutics Inc.
Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount
Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks
Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.
Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.
Asia's Nasdaq? Hong Kong‘s Quest To Be IPO Power House Has Blessings And Curses
Hundreds of executives showed up at an inaugural biotech summit organized by the Hong Kong Stock Exchange, setting the stage for a showdown between the territory and the most popular destination for biotech IPOs, Nasdaq in the US. Despite recent rule changes to allow pre-revenue biotechs to gain a listing more easily, executives still see hurdles that are associated with Hong Kong's close proximity to the very market it is trying to allure, mainland China.
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Immune Disorders
- Alias(es)
- FivePrime Therapeutics Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Five Prime Therapeutics Inc.
- Senior Management
-
William Ringo, Interim CEO
Francis Sarena, Chief Strategy Officer and Secretary
Helen Collins, MD, SVP, CMO - Contact Info
-
Five Prime Therapeutics Inc.
Phone: (415) 365-5600
111 Oyster Point Blvd.
South San Francisco, CA 94080
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice